Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxymethylcellulose + glycerine is a combination ophthalmic preparation used primarily for the symptomatic relief of dry eye disease. Carboxymethylcellulose acts as a lubricant and increases tear viscosity, mimicking natural tears to maintain ocular surface moisture and protect against further irritation. Glycerine functions as an ophthalmic demulcent, forming a soothing film over the mucous membrane surfaces of the eye to provide additional lubrication and comfort. Together, these agents temporarily relieve burning, irritation, and discomfort associated with dry eyes due to insufficient or poor-quality tear production[3][7]. The combination does not treat underlying causes but alleviates symptoms by stabilizing the tear film and reducing evaporation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylcellulose + glycerine.